How effective is ustekinumab for ulcerative colitis?

In the treatment of ulcerative colitis, ustekinumab (administered by infusion) was compared with placebo in two major studies. The first study involved 961 patients with moderately to severely active disease. The primary measure of effectiveness is the number of patients whose symptoms are gone or nearly gone 8 weeks after infusion. Symptoms were gone or nearly gone in 16%of patients treated with ustekinumab, compared with 5%of patients treated with placebo. In the second study, a total of 523 patients whose symptoms improved in the first study received ustekinumab every 8or Pan>Receive drug(subcutaneous injection) or placebo once every 12 weeks. After initiating treatment by subcutaneous injection for 44 weeks, there were 44% of patients in the Stelara group and 44% of patients in the Stelara group every 8 weeks. /span>12 weeks38%of patients in the ustekinumab group had their ulcerative colitis symptoms gone or nearly gone, compared with 24% of the placebo group. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to help you learn more about high-quality overseas drugs.